KR20240023665A - Pd-l1 발현에 기반한 종양 및 면역 세포 영상화 - Google Patents

Pd-l1 발현에 기반한 종양 및 면역 세포 영상화 Download PDF

Info

Publication number
KR20240023665A
KR20240023665A KR1020247003223A KR20247003223A KR20240023665A KR 20240023665 A KR20240023665 A KR 20240023665A KR 1020247003223 A KR1020247003223 A KR 1020247003223A KR 20247003223 A KR20247003223 A KR 20247003223A KR 20240023665 A KR20240023665 A KR 20240023665A
Authority
KR
South Korea
Prior art keywords
imaging
cancer
imaging agent
peptide
tumor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020247003223A
Other languages
English (en)
Korean (ko)
Inventor
스리다 니마가다
마틴 쥐. 폼퍼
사미트 채터지
보이치에흐 쥐. 레스니악
디라지 쿠마르
Original Assignee
더 존스 홉킨스 유니버시티
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 더 존스 홉킨스 유니버시티 filed Critical 더 존스 홉킨스 유니버시티
Publication of KR20240023665A publication Critical patent/KR20240023665A/ko
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/0002—General or multifunctional contrast agents, e.g. chelated agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/088—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins conjugates with carriers being peptides, polyamino acids or proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/005—Fluorescence in vivo characterised by the carrier molecule carrying the fluorescent agent
    • A61K49/0056—Peptides, proteins, polyamino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10—Organic compounds
    • A61K49/14—Peptides, e.g. proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/22—Echographic preparations; Ultrasonic imaging preparations
    • A61K49/222—Echographic preparations; Ultrasonic imaging preparations characterised by a special physical form, e.g. emulsions, liposomes
    • A61K49/225—Microparticles, microcapsules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Radiology & Medical Imaging (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Acoustics & Sound (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
KR1020247003223A 2016-12-23 2017-12-21 Pd-l1 발현에 기반한 종양 및 면역 세포 영상화 Ceased KR20240023665A (ko)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US201662438575P 2016-12-23 2016-12-23
US62/438,575 2016-12-23
US201762519534P 2017-06-14 2017-06-14
US62/519,534 2017-06-14
PCT/US2017/068025 WO2018119313A1 (en) 2016-12-23 2017-12-21 Tumor and immune cell imaging based on pd-l1 expression
KR1020197021481A KR102662725B1 (ko) 2016-12-23 2017-12-21 Pd-l1 발현에 기반한 종양 및 면역 세포 영상화

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
KR1020197021481A Division KR102662725B1 (ko) 2016-12-23 2017-12-21 Pd-l1 발현에 기반한 종양 및 면역 세포 영상화

Publications (1)

Publication Number Publication Date
KR20240023665A true KR20240023665A (ko) 2024-02-22

Family

ID=62627749

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020247003223A Ceased KR20240023665A (ko) 2016-12-23 2017-12-21 Pd-l1 발현에 기반한 종양 및 면역 세포 영상화
KR1020197021481A Active KR102662725B1 (ko) 2016-12-23 2017-12-21 Pd-l1 발현에 기반한 종양 및 면역 세포 영상화

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1020197021481A Active KR102662725B1 (ko) 2016-12-23 2017-12-21 Pd-l1 발현에 기반한 종양 및 면역 세포 영상화

Country Status (11)

Country Link
US (1) US11607466B2 (https=)
EP (1) EP3558395A4 (https=)
JP (3) JP7784103B2 (https=)
KR (2) KR20240023665A (https=)
CN (1) CN110366432A (https=)
AU (1) AU2017382282B9 (https=)
BR (1) BR112019012986A2 (https=)
CA (1) CA3048229A1 (https=)
IL (1) IL267572B2 (https=)
MX (1) MX2019007615A (https=)
WO (1) WO2018119313A1 (https=)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN119264211A (zh) 2018-08-27 2025-01-07 瑞泽恩制药公司 拉曼光谱在下游纯化中的应用
CN109512798B (zh) * 2019-01-15 2022-05-13 南京从一医药科技有限公司 一种用于抗肿瘤免疫治疗的药物组合物纳米体系
CN111662270A (zh) * 2019-03-05 2020-09-15 中国医学科学院药物研究所 碘同位素标记苄苯醚衍生物、及其制法和药物组合物与用途
CN110898234B (zh) * 2019-12-25 2020-12-22 河南大学 一种二维铋纳米复合材料及其制备方法和应用
TWI833056B (zh) 2019-12-31 2024-02-21 財團法人工業技術研究院 核酸藥物複合體以及其用途
CN112067586B (zh) * 2020-06-24 2021-08-03 江南大学 一种基于荧光淬灭拉曼增强的前列腺特异性抗原双信号光谱分析方法
KR20230086657A (ko) * 2020-08-07 2023-06-15 더 존스 홉킨스 유니버시티 프로그램된 사멸 리간드-1(pd-li) 발현의 영상화 및 표적화
DE102020130954A1 (de) 2020-11-23 2022-05-25 Universität Duisburg-Essen Markierungspartikel für Raman-Streuung und/oder Fluoreszenz-Strahlung
CN114853851B (zh) * 2021-02-04 2023-08-15 南方医科大学南方医院 靶向pd-l1多肽探针及其在制备pet显像剂中的应用
CN113341023B (zh) * 2021-06-30 2022-12-23 大连医科大学附属第一医院 一种基于液质联用的血清二氨基庚二酸的检测试剂盒及检测方法与应用
US20250135047A1 (en) * 2021-08-06 2025-05-01 The Johns Hopkins University Improved aluminum fluoride radiosynthesis of [18f]dk222
CN115364247A (zh) * 2021-09-15 2022-11-22 中国人民解放军海军军医大学第一附属医院 一种靶向显影剂、制备方法及其应用
CN114010655B (zh) * 2021-11-02 2023-02-03 安徽医科大学第一附属医院 一种识别和降解前列腺癌细胞表面的pd-l1的金纳米星及其制备方法和应用
CN114569745A (zh) * 2022-03-18 2022-06-03 哈尔滨医科大学 一种靶向pd-l1的多肽pet分子成像探针及其制备方法与应用
CN121889176A (zh) * 2023-09-20 2026-04-17 Trimt有限责任公司 用于体内定向pd-l1表达的功能化肽

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ542371A (en) * 2003-03-19 2008-10-31 Universitatsspital Basel Radiolabeled conjugates based on substance P and the uses thereof
EP3255060A1 (en) 2008-12-09 2017-12-13 F. Hoffmann-La Roche AG Anti-pd-l1 antibodies and their use to enhance t-cell function
WO2012074840A2 (en) * 2010-11-22 2012-06-07 The General Hospital Corporation Compositions and methods for in vivo imaging
WO2013032839A2 (en) 2011-09-02 2013-03-07 The Board Of Trustees Of The Leland Stanford Junior University Raman imaging devices and methods of moleclar imaging
WO2014043606A1 (en) * 2012-09-14 2014-03-20 The Johns Hopkins University Bacteria-specific labeled substrtates as imaging biomarkers to diagnose, locate, and monitor infections
US9308236B2 (en) * 2013-03-15 2016-04-12 Bristol-Myers Squibb Company Macrocyclic inhibitors of the PD-1/PD-L1 and CD80(B7-1)/PD-L1 protein/protein interactions
WO2016039749A1 (en) * 2014-09-11 2016-03-17 Bristol-Myers Squibb Company Macrocyclic inhibitors of the pd-1/pd-l1 and cd80 (b7-1)/pd-li protein/protein interactions
CA2969067A1 (en) * 2014-11-25 2016-06-02 Bristol-Myers Squibb Company Novel pd-l1 binding polypeptides for imaging
US9861680B2 (en) 2014-12-18 2018-01-09 Bristol-Myers Squibb Company Immunomodulators
US9944678B2 (en) 2014-12-19 2018-04-17 Bristol-Myers Squibb Company Immunomodulators
US20160222060A1 (en) 2015-02-04 2016-08-04 Bristol-Myers Squibb Company Immunomodulators
HRP20210644T8 (hr) 2016-05-19 2021-06-25 Bristol-Myers Squibb Company Imunomodulatori za pet-snimanje
CN107869033B (zh) * 2016-09-26 2020-10-02 青岛胶南海尔洗衣机有限公司 一种干衣机用正反转风扇及干衣机

Also Published As

Publication number Publication date
JP7784103B2 (ja) 2025-12-11
IL267572B1 (en) 2024-10-01
EP3558395A4 (en) 2020-08-12
AU2017382282B9 (en) 2025-02-13
WO2018119313A1 (en) 2018-06-28
CN110366432A (zh) 2019-10-22
JP2025118743A (ja) 2025-08-13
AU2017382282A1 (en) 2019-07-11
AU2017382282B2 (en) 2025-01-30
JP7680759B2 (ja) 2025-05-21
MX2019007615A (es) 2019-11-05
US11607466B2 (en) 2023-03-21
CA3048229A1 (en) 2018-06-28
IL267572B2 (en) 2025-02-01
JP2023052071A (ja) 2023-04-11
IL267572A (en) 2019-08-29
JP2020514278A (ja) 2020-05-21
KR20190102018A (ko) 2019-09-02
US20190314531A1 (en) 2019-10-17
EP3558395A1 (en) 2019-10-30
BR112019012986A2 (pt) 2019-12-03
KR102662725B1 (ko) 2024-04-30

Similar Documents

Publication Publication Date Title
KR102662725B1 (ko) Pd-l1 발현에 기반한 종양 및 면역 세포 영상화
Wester et al. Disclosing the CXCR4 expression in lymphoproliferative diseases by targeted molecular imaging
Miao et al. Small-animal PET imaging of human epidermal growth factor receptor positive tumor with a 64Cu labeled affibody protein
US12465660B2 (en) Compositions and methods for cancer imaging and radiotherapy
KR102665275B1 (ko) 신규 항인간 CEACAM5 항체 Fab 프래그먼트
JP2015532636A (ja) 部位特異的ｕＰＡＲ標的化のための１７７−Ｌｕ標識ペプチド
Kuil et al. Hybrid peptide dendrimers for imaging of chemokine receptor 4 (CXCR4) expression
Donnelly et al. The discovery and evaluation of [18F] BMS-986229, a novel macrocyclic peptide PET radioligand for the measurement of PD-L1 expression and in-vivo PD-L1 target engagement
US20230271923A1 (en) Imaging and targeting programmed death ligand-1 (pd-li) expression
US12285502B2 (en) HER3 peptides for imaging and radiotherapy
Privat et al. Development of an Immuno-SPECT/Fluorescent Bimodal Tracer Targeting Human or Murine PD-L1 on Preclinical Models
US11795197B2 (en) Peptide compositions for immuno-oncology molecular imaging and targeted drug delivery
Schreck et al. Radiometal Complexes as Pharmacokinetic Modifiers: A Potent 68Ga-Labeled Gastrin-Releasing Peptide Receptor Antagonist Based on the Macrocyclic Metal Chelator NODIA-Me
Dilworth et al. The radiopharmaceutical chemistry of Gallium (III) and Indium (III) for SPECT imaging
EA052886B1 (ru) Визуализация опухолевых и иммунных клеток на основе экспрессии pd-l1
Wang et al. Influence of chelator and near-infrared dye labeling on biocharacteristics of dual-labeled trastuzumab-based imaging agents
AU2024344671A1 (en) Functionalized peptides for in-vivo addressing of pd-l1 expression
Mishra et al. GALLIUM-68-LABELED PEPTIDE PET QUANTIFIES TUMOR EXPOSURE OF PD-L1

Legal Events

Date Code Title Description
A107 Divisional application of patent
PA0104 Divisional application for international application

St.27 status event code: A-0-1-A10-A18-div-PA0104

St.27 status event code: A-0-1-A10-A16-div-PA0104

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

R15-X000 Change to inventor requested

St.27 status event code: A-3-3-R10-R15-oth-X000

R16-X000 Change to inventor recorded

St.27 status event code: A-3-3-R10-R16-oth-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

R15-X000 Change to inventor requested

St.27 status event code: A-3-3-R10-R15-oth-X000

R16-X000 Change to inventor recorded

St.27 status event code: A-3-3-R10-R16-oth-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

R17-X000 Change to representative recorded

St.27 status event code: A-3-3-R10-R17-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E601 Decision to refuse application
PE0601 Decision on rejection of patent

St.27 status event code: N-2-6-B10-B15-exm-PE0601

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T13-X000 Administrative time limit extension granted

St.27 status event code: U-3-3-T10-T13-oth-X000

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PX0901 Re-examination

St.27 status event code: A-2-3-E10-E12-rex-PX0901

B17 Application discontinued following pre-grant review

Free format text: ST27 STATUS EVENT CODE: N-2-6-B10-B17-REX-PX0601 (AS PROVIDED BY THE NATIONAL OFFICE)

PX0601 Decision of rejection after re-examination

St.27 status event code: N-2-6-B10-B17-rex-PX0601

T11 Administrative time limit extension requested

Free format text: ST27 STATUS EVENT CODE: U-3-3-T10-T11-OTH-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T13 Administrative time limit extension granted

Free format text: ST27 STATUS EVENT CODE: U-3-3-T10-T13-OTH-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

T13-X000 Administrative time limit extension granted

St.27 status event code: U-3-3-T10-T13-oth-X000